LUXTURNA Continues to Lead in Retinal Gene Therapy with Increased Market Penetration | DelveInsight
DelveInsight's "LUXTURNA Market Size, Forecast, and Market Insight Report" highlights the details around LUXTURNA, a one-time ...
DelveInsight Business Research, LLP: LUXTURNA Continues to Lead in Retinal Gene Therapy with Increased Market Penetration | DelveInsight
LUXTURNA has significant market potential due to the high unmet need for effective treatments in rare genetic conditions. With its FDA approval for specific mutations in the RPE65 gene, it offers ...
Novethic15h
Compensation carbone : un tribunal allemand épingle Lufthansa pour publicité "trompeuse"
Lufthansa a été épinglé par un tribunal allemand pour ses publicités trompeuses sur des vols "neutres en carbone".
Novethic17h
Seize investisseurs institutionnels veulent développer l’investissement non coté sur la biodiversité
Seize investisseurs institutionnels français lancent un fonds non coté de 150 millions d’euros pour investir des solutions ...